Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
54 hedge funds and large institutions have $25M invested in Catalyst Pharmaceutical in 2016 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
33% more capital inflows, than outflows
Capital inflows: $2.56M | Capital outflows: $1.92M
10% more funds holding
Funds holding: 49 → 54 (+5)
0.59% more ownership
Funds ownership: 28.15% → 28.74% (+0.59%)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avoro Capital Advisors
New York
|
+$1.3M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$864K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$94.5K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$72.3K |
| 5 |
Virtu KCG Holdings
New York
|
+$61.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSA Capital Partners
London,
United Kingdom
|
-$812K |
| 2 |
BlackRock Advisors
Wilmington,
Delaware
|
-$191K |
| 3 |
Millennium Management
New York
|
-$181K |
| 4 |
Goldman Sachs
New York
|
-$149K |
| 5 |
Credit Suisse
Zurich,
Switzerland
|
-$146K |
CPRX Hedge Fund Activity: Q4 2016 in Review
54 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2016, worth a combined $25M — down 1.5% from $25.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CPRX positions and 5 closed out — a net gain of 5 holders — while 8 added to existing stakes and 12 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $1.3M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $812K sold.
- 54 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2016, up from 49 in Q3 2016.
- Funds reported $25M of Catalyst Pharmaceutical stock for Q4 2016, down 1.5% quarter-over-quarter.
- 10 funds opened new Catalyst Pharmaceutical positions in Q4 2016 and 5 closed out, a net change of +5 holders.
- The largest Catalyst Pharmaceutical buyer in Q4 2016 was Avoro Capital Advisors, an estimated $1.3M added.
- The largest Catalyst Pharmaceutical seller in Q4 2016 was GSA Capital Partners, an estimated $812K sold.
Based on aggregated 13F filings for Q4 2016.